CH
LXRX icon

CVI Holdings’s Lexicon Pharmaceuticals LXRX Stock Holding History

CVI Holdings’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$33.6K Buy
+20,000
New +$35.9K 0.03% 61

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

CVI Holdings's LXRX Position: Q2 2024 in Review

CVI Holdings opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2024: 20,000 shares worth $33.6K. The stake represents 0.03% of the portfolio and ranks #61 among its holdings.

127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • CVI Holdings held 20,000 shares of Lexicon Pharmaceuticals worth $33.6K as of Q2 2024.
  • Lexicon Pharmaceuticals was a new CVI Holdings position in Q2 2024.
  • Lexicon Pharmaceuticals made up 0.03% of CVI Holdings's portfolio in Q2 2024, its #61 holding.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on CVI Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.